Tafinlar for Melanoma: every route to paying for it

The routes, in order

1. 1

   Why this drug and this condition are paired

   TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.

   From the Indications and Usage text of the drug's FDA label. A label naming a condition is not a statement that the drug is approved, effective or covered for you.

   Label on openFDA, read 2026-11-10 · receipt

2. 2

   Medicare Part D: the yearly out-of-pocket threshold

   Found in our data
   CMS prints the Part D out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026).

   A benefit parameter of the standard Part D benefit. It applies to covered drugs under plan rules and is not a prediction of what you will pay. Your plan's formulary decides whether this drug is covered: check a formulary.

   CMS Table V-2, read 2026-11-08

3. 3

   Medicare negotiated price

   Not found in our data
   This drug is not in the CMS negotiated-price file we hold.
4. 4

   Manufacturer and foundation programs

   Found in our data
   • Novartis Patient Assistance Foundation (NPAF) (the program's own page) receipt

   A status is what the program's page says about taking applications, not whether you qualify. Each program has its own eligibility rules.

5. 5

   Charitable funds for Melanoma

   Found in our data
   We hold 3 funds for Melanoma: 0 open and 3 not open, read 2026-11-08.

   Every fund, with its award level, insurance supported and source, is on the Melanoma page. A fund pays for a condition's costs, not necessarily this drug.

6. 6

   Clinical trial access

   Not found in our data
   We hold no trial listing for this ingredient.

Questions